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no changes in serum insulin or glucose levels during icodextrinPharmacokinetics of icodextrin in peritoneal dialysis patients.
administration, indicating that icodextrin does not result inBackground. Icodextrin is a glucose polymer osmotic agent
hyperglycemia or hyperinsulinemia as occurs during dextrose-used to provide sustained ultrafiltration during long peritoneal
based dialysis. Serum sodium and chloride declined in paralleldialysis (PD) dwells. A number of studies have evaluated the
with the rise in plasma levels of icodextrin, supporting thesteady-state blood concentrations of icodextrin during repeated
hypothesis that these electrolyte changes are the result of theuse; however, to date the pharmacokinetics of icodextrin have
increased plasma osmolality due to the presence of icodextrinnot been well studied. The current study was conducted to de-
metabolites.termine the absorption, plasma kinetics and elimination of ico-
Conclusions. The pharmacokinetics of icodextrin in blooddextrin and metabolites following a single icodextrin exchange.
following intraperitoneal administration conforms to a simple,Methods. Thirteen PD patients were administered 2.0 L of
solution containing 7.5% icodextrin for a 12-hour dwell. Icodex- single-compartment model that can be approximated by zero-
trin (total of all glucose polymers) and specific polymers with order absorption and first-order elimination. A small amount of
degrees of polymerization ranging from two to seven (DP2 to intraperitoneal metabolism of icodextrin occurs but does not
DP7) were measured in blood, urine and dialysate during the contribute significantly to dialysate osmolality. The metabolism
dwell and after draining the solution from the peritoneal cavity. of absorbed icodextrin and the resultant rise in plasma levels
Results. A median of 40.1% (60.24 g) of the total adminis- of small glucose polymers (DP2 to DP4) do not result in hyper-
tered dose (150 g) was absorbed during the12-hour dwell. Plasma glycemia or hyperinsulinemia, but may result in a small de-
levels of icodextrin and metabolites rose during the dwell and crease in serum sodium and chloride.
declined after drain, closely corresponding to the one-compart-
ment pharmacokinetic model assuming zero-order absorption
and first-order elimination. Peak plasma concentrations (me-
Icodextrin is a mixture of high molecular weight, wa-dian Cpeak  2.23 g/L) were observed at the end of the dwell
(median Tmax  12.7 h) and were significantly correlated with ter-soluble glucose polymers isolated by fractionation of
patients’ body weight (R2  0.805, P  0.001). Plasma levels of hydrolyzed cornstarch [1]. The structure of icodextrin is
icodextrin and metabolites returned to baseline within 3 to 7 similar to glycogen, consisting of polysaccharide poly-
days. Icodextrin had a plasma half-life of 14.73 hours and a
mers of D-glucopyranose linked by -(1→4) and -(1→6)median clearance of 1.09 L/h. Urinary excretion of icodextrin
glucosidic bonds (Fig. 1). The structure of icodextrinand metabolites was directly related to residual renal function
(R2  0.679 vs. creatinine clearance, P  0.01). In the nine differs from glycogen in that it has a lower percentage
patients with residual renal function, the average daily urinary of -(1→6) linkages (10%) and hence is less highly
excretion of icodextrin was 473 77 mg per mL of endogenous branched. The majority of icodextrin polymers (85%)
renal creatinine clearance. Icodextrin metabolites DP2 to DP4
have a molecular weight between 1638 and 45,000 Dal-were found in the dialysate of subsequent dextrose exchanges,
tons, with only 6% having a molecular weight less thancontributing to their elimination from blood. Changes in intra-
peritoneal concentrations of icodextrin metabolites during the 1638 (equivalent to a polymer with 10 glucose units, or
dwell revealed a dual pattern, with a progressive rise in the a degree of polymerization of 10 [DP10]). Since icodex-
dialysate concentration of smaller polymers (DP2 to DP4) and trin is a polydispersed mixture of polymers with varying
a progressive decline in the dialysate concentrations of the
chain lengths, its molecular weight is characterized bylarger polymers (DP5 to DP7), suggesting some intraperitoneal
both a number average (Mn) and a weight average (Mw)metabolism of the glucose polymers. This increase in dialysate
metabolite levels, however, did not contribute significantly to molecular weight. The Mn for icodextrin, that is, the
dialysate osmolality. In addition, some diffusion of maltose arithmetic mean of the molecular weights of the individ-
(DP2) from blood to dialysate may have occurred. There were ual glucose polymer molecules, ranges from 5000 to 6500
Daltons and the Mw [equal to the sum of (weight of
molecules times molecular weight) for all molecular spe-Key words: dialysate, glucose polymer osmotic agent, ultrafiltration,
renal replacement therapy. cies divided by the total weight of all molecules] ranges
from 13,000 to 19,000 Daltons. 2002 by the International Society of Nephrology
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conventional methods. In addition, we and others have
developed and validated methods for the quantitation of
icodextrin and metabolites DP2 to DP7 in plasma, urine
and dialysate [12]. We therefore employed these meth-
ods in a detailed evaluation of the pharmacokinetics and
elimination of icodextrin and metabolites following a sin-
gle exchange. This study expands the available knowl-
edge of the clinical pharmacology of icodextrin following
its intraperitoneal administration and fills the gaps in our
understanding of the fate of icodextrin and the metabolic
consequences of icodextrin and its metabolites.
EXPERIMENTAL PROCEDURES
Study subjects
Fig. 1. United States Adopted Names (USAN) structure of icodextrin.
The study was conducted in accordance with the ethi-
cal principles of the Declaration of Helsinki. Thirteen
peritoneal dialysis patients were enrolled from three hos-Glucose and other small molecules are absorbed from
the peritoneal cavity primarily by diffusion across the peri- pital centers. The patients were treated with PD for at
least three months prior to enrollment. Standard PDtoneal capillary endothelium [2]. For icodextrin, how-
ever, this diffusive component is limited, and absorption prescriptions for the preceding 30 days included a long
dwell of 8 to 16 hours and a typical fill volume of 2.0 oroccurs primarily due to convective fluid movement out
of the peritoneal cavity via the lymphatics [3]. As a result, 2.5 L. All patients were at least 18 years of age and re-
quired a minimum of four peritoneal dialysis exchangesthe osmotic pressure created by icodextrin is relatively
constant, and ultrafiltration (UF) is sustained throughout per day. Patients were excluded if they had acute or
chronic exit site or tunnel infection, had a recent episodea long dwell [4–7]. Nevertheless, approximately 20 to
35% of the administered icodextrin solution is reported of peritonitis (within 30 days of screening), were known
to be HIV positive, had known allergy to glucose poly-to be absorbed from the peritoneal cavity during a long
dwell [3, 5]. mers or a history of glycogen storage disease, had other
serious disease such as malignancy or hepatic disease,Absorbed icodextrin is hydrolyzed by circulating -amy-
lases to yield glucose polymers with a degree of polymer- were pregnant or lactating, or had an injury or illness
requiring hospitalization within the preceding 30 days.ization less than that of the original polymer, including
maltose (DP2), maltotriose (DP3) and maltotetraose Patients who had previous exposure to icodextrin within
the preceding 60 days, were participating in another in-(DP4) [3]. These small oligosaccharides are the principal
metabolites of icodextrin observed in blood during re- terventional study, or had used another investigational
product within thirty days of treatment also were ex-peated exposure to icodextrin [5, 6]. Maltose and other
icodextrin metabolites may be further metabolized to cluded. All patients provided written informed consent
prior to enrollment.glucose by tissue maltases, excreted into the urine (if
the patient has residual renal function) or eliminated by The 13 patients ranged in age from 29 to 77 years
(mean 53.8 years old). Mean body weight was 89.6 kgperitoneal dialysis [3]. However, the relative contribu-
tions of each of these routes of elimination of icodextrin (range 50 to 140.5). Five patients were male and eight
patients were female. Six patients were Caucasian, sixand its metabolites are not known.
Numerous clinical studies confirm that icodextrin is were African American and one was Hispanic. Primary
causes of renal disease were glomerulonephritis (N safe and effective as an alternative osmotic agent for the
long dwell, and several clinical studies have measured 5), hypertensive nephropathy (4), diabetic nephropathy
(1), obstructive nephropathy (1), and “other” (2). Sixlevels of icodextrin and maltose at steady-state following
repeated administration [5, 6, 8–11]. However, character- patients were diabetic (all type 2).
Six patients began their dialysis treatment with PDization of the plasma kinetics, metabolism and elimina-
tion of icodextrin has been limited by the absence of and seven patients began dialysis treatment using hemo-
dialysis. The duration of dialysis ranged from 3.7 to 266.2available analytical techniques, the complexity of the
polymer mixture, and lack of a radiolabeled precursor for months (mean 40.7 months). The mean time from start-
ing current PD was 20.3 months. Seven of the patientsicodextrin. Nevertheless, the total mixture of icodextrin
polymers can be readily quantitated in plasma and other were receiving continuous ambulatory peritoneal dialysis
(CAPD) and six patients were receiving automated peri-biological samples by the hydrolysis of total carbohy-
drate to glucose followed by determination of glucose by toneal dialysis (APD). One patient had previously re-
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ceived a transplant and two patients had reported an was analyzed for the above chemistries plus liver enzymes
and hematology as for the pre-dwell blood sample. Twenty-episode of peritonitis within the previous six months.
The mean time since the most recent peritonitis incident four-hour urine specimens (from patients with sufficient
urine output) were analyzed for icodextrin, metabolites,was 6.4 months.
sodium, chloride, urea nitrogen and creatinine.
Study design and sample collections
Analytical methodsFollowing screening and informed consent, patients
were admitted to the hospital ward for a 24-hour stay. Icodextrin was quantified in plasma, urine and dialy-
sate by exhaustive hydrolysis of all glucose polymers toA venous catheter was inserted and a pre-dwell blood
sample was collected (time 0) for analysis of icodextrin glucose using the enzyme amyloglucosidase. Free glucose
(determined prior to hydrolysis) was subtracted fromand metabolites (DP2 to DP7), serum chemistries (so-
dium, chloride, urea nitrogen, creatinine, glucose, insu- the result of hydrolysis to obtain the icodextrin concen-
tration. According to this method, reported icodextrinlin, bilirubin, aspartate aminotransferase, alanine amino-
transferase and alkaline phosphatase) and hematology measurements comprise the sum of all glucose polymers
with a degree of polymerization (DP) greater than or(complete blood count with differential). Patients were
requested to void and discard their urine; all urine voided equal to maltose (DP2).
For determination of icodextrin in plasma, 0.25 mL ofduring the following 24 hours was collected and refriger-
ated for further analysis. Each patient was then admin- plasma was diluted 1:1 with a solution containing 1 mg/mL
amyloglucosidase (Sigma Chemical Company, St. Louis,istered a 2.0 L exchange of 7.5% icodextrin solution
with the following formulation: 7.5 g/dL icodextrin, 132 MO, USA) and incubated at 55C for approximately 30
minutes to allow complete hydrolysis of icodextrin tomEq/L sodium, 96 mEq/L chloride, 3.5 mEq/L calcium,
0.5 mEq/L magnesium and 40 mEq/L lactate (pH 5.2) glucose. Glucose concentrations were measured in the
sample prior to hydrolysis and post-hydrolysis using glu-(Extraneal; Baxter Healthcare Corporation, Deerfield,
IL, USA). The total dose of icodextrin administered in cose hexokinase, and icodextrin concentrations were cal-
culated as the difference between glucose values beforethe 2 L bag was 150 g.
The icodextrin solution was left in the peritoneal cavity and after amyloglucosidase hydrolysis, taking into ac-
count the dilution factor. For determination of icodextrinfor a 12-hour dwell, during which blood and dialysate
samples were collected. Blood was collected at 2, 4, 8 and in dialysate obtained during the icodextrin dwell, sam-
ples (0.1 mL) were diluted with 0.9 mL of amyloglucosi-12 hours for measurement of icodextrin and metabolites,
serum insulin, glucose, sodium and chloride. Dialysate dase solution and assayed as above. For dialysate samples
obtained following exchanges with glucose-based perito-samples were collected at 0, 2, 4, 8 and 12 hours using an
InterLink System and assayed for icodextrin, icodextrin neal dialysis solution, samples were preincubated (1:2)
with glucose oxidase (1200 U/mL; Sigma Chemical Co.)metabolites, sodium, chloride, urea and osmolality. The
zero-hour dialysate sample was collected within approxi- to eliminate baseline glucose. All procedures were vali-
dated for precision, accuracy, specificity, linearity, limitmately three minutes of icodextrin administration. Pa-
tients were rotated from side to side for at least two of detection and sample stability. The above analyses were
conducted by Baxter Healthcare Corporation’s Clinicalcomplete rotations prior to dialysate sampling.
At 12 hours, the solution was drained from the perito- Laboratory Services (Round Lake, IL, USA).
Maltose (DP2), maltotriose (DP3), maltotetraose (DP4),neal cavity and the patients resumed dialysis using dex-
trose-containing solutions (Dianeal; Baxter Healthcare maltopentaose (DP5), maltohexaose (DP6) and malto-
heptaose (DP7) were individually quantified in blood,Corporation) with three additional manual exchanges
performed for the balance of the 24 hours since the ico- spent dialysate and urine (for patients with urine output)
using high performance anion exchange chromatographydextrin dwell was initiated. Ten minutes after the first
Dianeal dwell, a dialysate sample was collected for analy- with pulsed amperometric detection (HPAE-PAD) as
previously described [12]. Quantitation of each of thesis of icodextrin, metabolites, sodium and chloride. Addi-
tional dialysis exchanges (using Dianeal) were conducted metabolites was based on a six-point working curve con-
structed using the peak area responses for purified oligo-at 16, 20 and 24 hours, with samples of the effluent dialy-
sate collected after each exchange. Blood samples were saccharide standards. Analysis of icodextrin metabolites
was performed by the Renal Division, Baxter Healthcarecollected at 16 and 24 hours and a final urine collection
was made at 24 hours. Patients were discharged and Corporation (McGaw Park, IL, USA).
requested to return on days 3, 7, 14 and 28 for collection
Pharmacokinetic analysesof blood samples on an outpatient basis. Blood samples
collected on days 3, 7 and 14 were analyzed for icodextrin For the purposes of the kinetic analysis, icodextrin was
defined as the sum of all glucose polymers greater thanand metabolites, serum sodium, chloride, urea nitrogen,
creatinine, glucose and insulin. The 28-day blood sample or equal to DP2 as described above. A pharmacokinetic
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model based on a constant rate of absorption for a prede-
termined time interval was selected [13], since this was
expected to approximate the situation of a fill, dwell and
drain in peritoneal dialysis. Absorption of icodextrin into
the systemic circulation was estimated from the disappear-
ance rate of icodextrin from the peritoneal cavity. Dialy-
sate concentration-time data were analyzed using a one-
compartment model and assuming zero-order kinetics.
Although the absorption of icodextrin is not strictly a
zero-order process, the linear approximation provided a
very good fit. The dialysate concentration (Cd, g/L) of
icodextrin at time t (hours) was therefore described by
the equation
Cd  C0 
K0t
V
, (Eq. 1)
where C0 is the concentration of icodextrin at time zero
(g/L), K0 is disappearance rate constant (g/h), and V is
Fig. 2. Absorption of icodextrin. The disappearance of icodextrin fromthe dialysate instillation volume (fixed at 2.0 L). The the peritoneal cavity was approximated using zero-order kinetics, con-
amount of icodextrin absorbed (A) at the end of the sistent with a constant rate of fluid absorption, for example, via perito-
neal lymphatic pathways. The median dose of absorbed icodextrin waslong-dwell exchange was estimated using the equation:
60.24 g (40.1% of instilled). The intersection of the ordinate at a value
A  K0  t, where t is the dwell time (12 hours). For slightly lower than the icodextrin concentration of infused solution (75
g/L) is likely due to the residual volume of dialysate in the peritonealthe kinetic modeling, it was assumed that K0 was inde-
cavity at the time of infusion. Note that appreciable icodextrin (40pendent of changes in peritoneal volume. g/L) remained in the peritoneal cavity at the end of the 12-hour dwell
Concentrations of icodextrin in plasma were analyzed (R2  0.95).
assuming a one-compartment model with approximately
zero-order absorption and first-order elimination [14]. The
RESULTSmodel parameters were estimated using the equation
All thirteen patients enrolled in the study received the
12-hour exchange using icodextrin and all patients wereC(t) 
K0
CL
[1  eKe*t] * eKe*t	, (Eq. 2)
included in the analysis of pharmacokinetic parame-
ters. Two patients withdrew from the study prior to thewhere C(t) is the blood concentration of total icodextrin
final study visit at day 28 (one by patient choice after(in g/L) at time t; K0 is the absorption rate constant (g/h);
the day 3 study visit and one who failed to show for theKe is the elimination rate constant (hour1); t is time
day 28 visit). The other eleven patients completed allsince start of the icodextrin dwell (in hours); t	 is time
visits through day 28.since drain of the icodextrin dwell (in hours); and CL is
the clearance rate (in L/h; note that t	  0 when t 
 Absorption of icodextrin
drain time for that patient). Area under the curve (AUC)
Concentrations of icodextrin in the peritoneal cavity
was determined according to the trapezoidal rule. Distri-
declined in an approximately linear fashion, consistent
bution volume, half-life, and total body clearance were with fluid absorption via convective pathways such as
estimated directly through non-linear regression (curve the peritoneal lymphatics (Fig. 2). All patients showed
fitting) and Tmax and Cpeak were estimated from model a similar rate of disappearance of icodextrin from the
parameters [13]. peritoneal cavity during the dwell. Model-predicted val-
ues for dialysate concentrations of icodextrin during theStatistical analyses
12-hour dwell corresponded closely to measured values.
The SAS software program (SAS Institute, Cary, NC, A median of 60.24 g (40.1%) of the administered dose
USA) was used to generate a linear fit and to estimate was absorbed during the 12-hour dwell (range 36.29 to
the disappearance rate constant K0 (g/h) and the concen- 102.37 g; 24.2 to 68.3%). The median disappearance rate
tration of icodextrin at time zero (C0) (g/L) for each constant (K0) was 5.02 g/h (range 3.02 to 8.53 g/h).
patient. A separate SAS program was used to estimate
Plasma kinetics of icodextrin and metabolitesthe model parameters for plasma kinetics. All values are
reported as mean  standard error (SE) unless other- Peak plasma concentrations of icodextrin (median
Cpeak  2.23 g/L; range 1.49 to 3.28 g/L) were observedwise indicated.
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Fig. 4. Peak plasma concentration versus body weight. Individual pa-Fig. 3. Plasma icodextrin profile. Mean plasma icodextrin levels peaked
tient peak plasma concentrations of icodextrin (Cmax) correlated signifi-at the end of the 12-hour dwell (Tmax  12.7 hours) and returned to cantly with patients’ body weight (measured after drain and prior tobaseline within seven days. Plasma data were consistent with a one-
icodextrin administration; R2  0.8052).compartment model with zero-order absorption and first-order elimina-
tion. Cmax  maximum plasma concentration, 2.23 g/L; T1/2  plasma
half-life, 14.73 hours; CL  clearance rate from plasma, 1.09 L/h.
HPAE-PAD, but levels of this molecule were unaffected
by icodextrin administration.
at the end of the long dwell (median Tmax  12.7 hours;
Urinary excretion and elimination by dialysisrange 12.0 to 14.3 h). Plasma levels returned to baseline
values within seven days after administration (Fig. 3). Urinary excretion of icodextrin during the 24 hours
Peak plasma levels correlated significantly with patients’ following administration was directly proportional to the
body weight (Fig. 4; P  0.0001), as well as with body level of residual renal function. Since four patients were
mass index and total body water (estimated using the anuric, urinary excretion data were available for nine
Watson formula; data not shown), reflecting the normal patients. The mean creatinine clearance for these nine
relationship of plasma drug levels to volume of distribu- patients was 5.03  1.54 (SE) mL/min, and urea clear-
tion. The measured and model-predicted values for plasma ance 1.81  0.73 mL/min. Urinary excretion of icodex-
concentrations of icodextrin corresponded closely for trin was directly correlated with the level of renal func-
each patient, indicating good fit to the kinetic model. tion (R20.679 vs. renal creatinine clearance, P  0.01;
Mean, median and ranges for the kinetic parameters R20.681 vs. renal urea clearance, P  0.01). A mean
are provided in Table 1. Icodextrin had a median plasma 2.22  0.62 g of icodextrin was recovered in the 24-hour
half-life of 14.73 hours (range 10.88 to 21.27 hours) and urine collection with a range of values corresponding to
a median clearance rate of 1.09 L/h (range 0.55 to 2.28 the wide range of residual renal function. The average
L/h). Both half-life and clearance were significantly cor- excretion of icodextrin was 473  77 mg per mL of
related with the level of residual renal function (R2  creatinine clearance per 24 hours. The profile of ico-
0.544 and 0.517, respectively, vs. renal creatinine clear- dextrin metabolites in urine mirrored that of plasma
ance; P  0.01). The median distribution volume was (DP2DP3DP4), with lower levels of DP2 in urine
20.06 L (range 11.28 to 40.43 L), and the AUC calculated than in plasma, likely due to intrarenal metabolism of
by the trapezoidal method had a median of 153.69 g/L/h maltose by brush border maltases.
(range 55.13 to 180.60). Elimination of icodextrin and metabolites into the di-
Plasma levels of maltose (DP2), maltotriose (DP3) alysate was determined by measurements of icodextrin
and maltotetraose (DP4) increased following icodextrin and DP2 to DP7 in dialysate obtained from the three
administration with a profile similar to that of total ico- exchanges following the 12-hour dwell. The concentra-
dextrin (Fig. 5). Peak values were achieved following the tion of icodextrin in the dialysate effluent was 3.41 
end of the dwell and declined to baseline levels by three 0.55 g/L following the first dextrose exchange, 0.85 
to seven days. Peak plasma concentrations of DP2, DP3 0.11 g/L following the second exchange, and 0.47  0.05
and DP4 were 0.53, 0.49 and 0.17 g/L, respectively. No g/L following the third exchange (Table 2). The rela-
statistically significant increases from baseline were ob- tively high concentration of icodextrin in the first ex-
served for plasma levels of DP5 to DP7. A small amount change was likely due to the dilution of the fresh dialy-
of DP5 or other carbohydrate with a superimposed elu- sate with the residual volume of icodextrin solution from
the previous drain. Consistent with this suggestion, ico-tion profile was detected in baseline plasma samples by
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Table 1. Kinetic parameters
Dose K0 % Ke Clearance Tmax CPeak Distribution AUC Half life
g g/h Absorbed h1 rate L/hr hours mg/L volume L g/L/h hours
Mean 62.13 5.1776 41.42 0.0475 1.0946 12.77 2294.91 22.73 125.28 15.20
Standard error 5.11 0.4258 3.41 0.0027 0.1413 0.15 164.70 2.31 13.43 0.89
Minimum 36.29 3.0240 24.19 0.0326 0.5465 12.02 1486.46 11.28 55.13 10.88
Median 60.24 5.0204 40.16 0.0470 1.0893 12.70 2231.38 20.06 153.69 14.73
Maximum 102.37 8.5310 68.25 0.0637 2.2769 14.33 3282.04 40.43 180.60 21.27
N  13.
Table 2. Concentration of icodextrin and metabolites DP2 to
DP4 in dialysate from the three exchanges after the single
12-hour exchange
Mean concentration g/L (N  13)
1st exchange 2nd exchange 3rd exchange
Icodextrin 3.410.55 0.850.11 0.470.05
DP2 0.270.031 0.290.039 0.240.024
DP3 0.260.034 0.250.035 0.180.021
DP4 0.120.017 0.0750.011 0.0390.007
Sum of DP2 to DP4 0.65 0.62 0.46
tern: dialysate concentrations of the larger polymers (DP5
to DP7) decreased progressively during the dwell, while
dialysate concentrations of smaller polymers (DP2 to
DP4) were observed to increase (Fig. 6). The decline in
the dialysate concentrations of the larger metabolites
Fig. 5. Plasma profile for icodextrin metabolites. Mean plasma levels could be due either to their absorption from the perito-
(N 13) of maltose (DP2; ), maltotriose (DP3;) and maltotetraose neal cavity or to intraperitoneal metabolism by amylase.
(DP4;) peaked at approximately 12 to 16 hours and declined thereaf-
Correspondingly, the rise in the dialysate concentrationster. Plasma maltopentaose (DP5;), maltohexaose (DP6;) and malto-
heptaose (DP7; ) did not increase significantly from baseline during of smaller metabolites could be the result of either diffu-
icodextrin administration. sion from the systemic circulation or due to intraperitoneal
metabolism of larger polymers, or both. In order to esti-
mate the relative contributions of these two processesdextrin concentrations determined in samples obtained
to changes in dialysate concentrations of DP2 to DP4, the10 minutes after infusion of the first dwell were also ele-
plasma and dialysate concentrations during the 12-hourvated (2.99 0.45 g/L). Metabolite concentrations in the
dwell were compared (Fig. 7).three subsequent dialysis exchanges were approximately
In the case of maltose (Figure 7A), plasma concentra-0.20 to 0.30 g/L for DP2 and DP3 and 0.12 g/L or less
tions exceeded the dialysate concentrations by the fourthfor DP4 (Table 2). Concentrations of DP5 to DP7 in
hour of the dwell and were greater for the remainder ofdialysate were very low following the first Dianeal ex-
the 12-hour dwell, suggesting that the increase in dialy-change (0.002 g/L) and negligible thereafter. The sum
sate concentrations of DP2 could result from diffusionof metabolites DP2 to DP4 represented 19% of the total
from blood to dialysate. The rise in the dialysate concen-glucose polymers measured in dialysate after the first
trations of metabolites DP3 and DP4, however, was un-exchange. However, by the third exchange, the sum of
likely to be due to diffusion from the systemic circula-metabolites DP2 to DP4 represented approximately 98%
tion, as the concentration in peritoneal fluid remainedof the total polymer recovered from the dialysate. The
higher than the plasma levels of these two metabolitesrecovery of predominantly smaller sized metabolites
throughout the length of the dwell (Fig. 7 B, C). These(DP2 and DP3) during these latter exchanges suggests
observations suggest that intraperitoneal metabolism ofdiffusion of these metabolites from the blood into the
icodextrin contributed to the increase in dialysate con-dialysate solution. The total amount of icodextrin re-
centrations of DP3 and DP4.moved during the three dialysis exchanges (including
Nevertheless, total dialysate concentrations of icodex-that due to residual volume) was approximately 10 g.
trin metabolites (DP2 to DP7) did not contribute signifi-
Intraperitoneal metabolism cantly to the rise in dialysate osmolality during the 12-
hour dwell (Table 3). Although mean dialysate osmolal-Changes in the intraperitoneal concentrations of me-
tabolites during the 12-hour dwell revealed a dual pat- ity increased from 282 mOsm/kg at the beginning of the
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Fig. 6. Dialysate levels of icodextrin metabolites. Mean dialysate levels
(N  13) of icodextrin metabolites during the 12-hour dwell revealed
a dual pattern, with a progressive rise in the dialysate concentration of
smaller polymers (DP2 to DP4) and a progressive decline in the dialysate
concentrations of the larger polymers (DP5 to DP7). Symbols are: maltose
(DP2;), maltotriose (DP3;), maltotetraose (DP4;), maltopentaose
(DP5; ), maltohexaose (DP6; ), and maltoheptaose (DP7; ).
dwell to 307 mOsm/kg at 12 hours, the calculated rise
in osmolarity due to icodextrin metabolites DP2 to DP7
(the sum of the molar concentrations of each metabolite)
during this period was negligible (0.2 mOsm/L between
0 and 12 hours). In contrast, dialysate concentrations of
other osmolytes (urea and sodium) increased signifi-
cantly during the 12-hour dwell, thereby contributing
significantly to the rise in dialysate osmolality.
Serum insulin and glucose
There was no evidence for an increase in serum levels
of insulin or glucose during the 12-hour exchange (Fig. 8).
Mean baseline levels for serum insulin were 75.6  19.4
U/mL and remained between 54.9 and 85.4 U/mL
throughout the 12-hour dwell. Mean serum glucose was
Fig. 7. Time course of dialysate and plasma levels of icodextrin metabo-
7.4  0.7 mmol/L (133  13 mg/dL) at baseline and lites. (A) Maltose (DP2); (B) maltotriose (DP3); (C ) maltotetraose
(DP4). Symbols are: () plasma concentrations; () dialysate concen-also did not vary significantly over the dwell period.
trations. N  13.Therefore, absorption of icodextrin did not result in hy-
perinsulinemia or hyperglycemia during the dwell.
clines in serum sodium and chloride paralleled the riseSodium and chloride
in plasma icodextrin (Fig. 9). Dialysate sodium concen-Mean serum sodium declined significantly by hour 8
trations increased during the dwell (Table 3) with noof the dwell (from 140.9  0.7 to 139.0  0.9 mmol/L,
evidence for sodium sieving as observed with glucose1.92 mmol/L; P  0.003) and remained significantly
based solutions (D/P sodium  0.929, 0.952 and 0.958below baseline at 24 hours (3.15 mmol/L; P  0.001).
at 0, 2 and 4 hours, respectively).The decrease in mean serum chloride was evident by
hour 2 of the dwell (1.46 mmol/L; P  0.003) and re-
DISCUSSIONmained below baseline values at 24 hours (4.23 mmol/L;
P  0.001). Mean serum sodium and chloride were not The current study provides a detailed investigation of
the pharmacokinetics of icodextrin during a single dial-significantly different from baseline at day 3. The de-
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Table 3. Mean dialysate osmolality during the 12-hour dwell: Osmolar contributions of icodextrin metabolites
(DP2 to DP7) and other osmolytes
0 hours 2 hours 4 hours 8 hours 12 hours
Measured osmolality mOsm/kg 282 296 (14)a 300 (18) 304 (22) 316 (34)
DP2 mmol/L 0.5 0.5 0.5 0.8 1.0
DP3 mmol/L 0.6 0.6 0.7 0.9 1.1
DP4 mmol/L 0.4 0.4 0.5 0.6 0.7
DP5 mmol/L 0.5 0.4 0.3 0.2 0.2
DP6 mmol/L 0.6 0.5 0.4 0.3 0.2
DP7 mmol/L 0.6 0.5 0.4 0.3 0.2
Total metabolitesb mOsm/L 3.2 2.9 (0.3) 2.8 (0.4) 3.1 (0.1) 3.4 (0.2)
Urea mmol/L 2.3 11.1 (8.8) 14.1 (11.8) 16.6 (14.3) 16.0 (13.7)
Na mmol/L 130.9 133.9 (6.0)c 134.3 (6.8)c 132.9 (4.0)c 134.6 (7.4)c
a Values in parentheses are change from baseline (0 hours)
b Calculated osmolar contribution of metabolites DP2 to DP7
c Calculated osmolar contribution of rise in both sodium and chloride (sodium  2)
Fig. 9. Temporal relationship between serum sodium and plasma ico-
dextrin levels. (A) Plasma icodextrin concentration; (B) serum sodium.
N  13.
Fig. 8. Serum glucose and insulin during the 12-hour dwell. There were
no significant changes in serum glucose or insulin during the 12-hour
dwell. (A) Serum glucose; (B) serum insulin. N  13. 20% of icodextrin (and metabolites) are eliminated by
renal excretion and dialysis, with the remainder ultimately
metabolized to glucose. However, in spite of this metabo-ysis dwell as well as new data on the intraperitoneal me-
lism to glucose, icodextrin does not result in hyperglyce-tabolism of icodextrin and its clinical pharmacology. To-
mia or hyperinsulinemia, in contrast to hypertonic dex-tal icodextrin and individual glucose polymers from mal-
trose solutions. Though this study presents evidence fortose (DP2) to maltoheptaose (DP7) were measured in
intraperitoneal metabolism of icodextrin, the degree ofplasma, urine and dialysate to precisely determine the ab-
intraperitoneal metabolism is small and does not contrib-sorption, metabolism and elimination of icodextrin fol-
ute significantly to dialysate osmolality. These and otherlowing intraperitoneal administration. The excellent fit
observations shed important new light on the pharmacol-of the data to a simple, one-compartment pharmacoki-
ogy and metabolism of icodextrin in PD patients.netic model assuming zero-order absorption and first-
The rate of disappearance of icodextrin from the peri-order elimination suggests that the fate of icodextrin can
toneal cavity was consistent with the constant rate ofbe readily explained by convective uptake from the peri-
fluid transport from the peritoneal cavity (for example,toneal cavity and steady rates of elimination and metabo-
via the lymphatics). Considering the rate of decline in ico-lism. Mass balance of icodextrin approximated from these
data indicate that, following a single exchange, at least dextrin concentration (5 g/h) and the concentration of
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the initially administered solution (0.075 g/mL), the rate the total icodextrin polymer in plasma, indicating rapid
metabolism of larger polymers by amylase as they en-of fluid reabsorption can be estimated: 5 g/h (0.083 g/min)
divided by 0.075 g/mL  1.1 mL/min. This value is very tered the circulation. Since DP2 and DP3 are not effec-
tive substrates for amylase [19] and there is no maltasesimilar to the reported rates of convective fluid reabsorp-
tion and lymphatic absorption in PD patients [15–17]. present in the human blood [20], these metabolites ac-
count for most of the icodextrin metabolites in blood.The inter-patient variability in the icodextrin absorption
rate (range 3.02 to 8.53 g/h) is also within the reported DP4 is a partial substrate for amylase [19], leading to
lower plasma levels. Larger oligosaccharides, for exam-variation in the rate of lymphatic absorption [17]. These
findings are therefore consistent with the uptake of ico- ple, DP5 to DP7, which are effective substrates for amy-
lase, did not increase significantly from baseline in thisdextrin from the peritoneal cavity by convective path-
ways including the lymphatics. study. The presence of small quantities of DP5 to DP6
in the circulation may be due to absorption from thePrevious studies reported icodextrin absorption of
19.6% and 33.5% during 8-hour and 12-hour dwells, re- peritoneal cavity, as these polymers are originally pres-
ent in the icodextrin solution when instilled into thespectively [3]. Since the rate of absorption is nearly con-
stant during the dwell, the percentage of icodextrin ab- peritoneal cavity (Fig. 6).
Icodextrin contains a small percentage of -(1→6) glu-sorbed is directly related to the length of the dwell.
Therefore, the value for icodextrin absorption during cosidic linkages (7%), potentially resulting in forma-
tion of -(1→6) linked metabolites. However, there isthe 12-hour dwell in this study (40%) is comparable to
the previously reported value of 33.5% [3]. Calculating no evidence of increased blood levels of -(1→6) linked
glucose dimmers (isomaltose) or other -(1→6) linkedthe rate of disappearance based on direct measurements
of dialysate icodextrin during the dwell, as in this study, metabolites. Isomaltose is known to be elevated in pa-
tients with chronic renal failure [21] but paradoxicallymost likely provides a more accurate determination than
previous methods that depended on measuring the ef- decreases during icodextrin administration [22]. The
presence of other -(1→6) linked metabolites, such asfluent volume and icodextrin concentration at the end
of the dwell. A portion of absorbed icodextrin may be the singly branched polymers 62-maltosyl maltotriose and
63-maltosyl maltotriose, has been investigated, but onlytransported initially into peritoneal tissues, as occurs for
other macromolecules [18]. However, peak plasma levels minor peaks with retention times corresponding to these
metabolites were observed in plasma from patients treatedof icodextrin were attained by the end of the 12-hour
dwell, indicating a relatively short transit time of icodex- with icodextrin (abstract; Patel et al, Perit Dial Int 20:140,
2000). In any event, -(1→6) linked sugars are readilytrin from lymphatic vessels or peritoneal tissues into blood.
The kinetics of icodextrin elimination from plasma fit metabolized to glucose by intracellular enzymatic ma-
chinery involved in the metabolism of glycogen.a one-compartment model with first-order elimination.
Elimination of icodextrin occurred by both renal excre- Icodextrin and amylase-derived metabolites that are
not eliminated by renal excretion or dialysis ultimatelytion and by dialysis during subsequent exchanges. The
contribution of renal excretion was directly proportional undergo metabolism to glucose by intracellular enzymes,
including -glucosidase (maltase), phosphorylase, andto the level of residual renal function and averaged about
2.2 g/day for the nine patients with urinary output (about debranching enzymes such as amylo-1,6-glucosidase. Mal-
tase, which hydrolyzes maltose to glucose, is found in4% of the absorbed dose). A significant portion of ico-
dextrin elimination by dialysis involved removal due to a variety of extrarenal tissues as well as in the kidney
[20, 23] and maltose readily enters tissues by diffusionresidual volume in the peritoneal cavity following the
icodextrin dwell, with the remainder due to dialysis of (abstract; Young and Weser, J Clin Invest 53:87A, 1974).
Extrarenal maltase is reported to contribute to maltosepredominantly smaller metabolites DP2 and DP3 (Ta-
ble 2). The total amount of icodextrin removed during metabolism in patients with renal failure [24]. Phosphor-
ylase removes -(1→4) linked glucosyl residues from thethe three exchanges following the icodextrin dwell was
approximately 10 g, or about 17% of the absorbed dose. non-reducing end of glucose polymers to yield glucose
1-phosphate, while amyloglucosidase and other debranch-Therefore, the total amount of icodextrin eliminated by
peritoneal dialysis and renal excretion and dialysis dur- ing enzymes hydrolyze -(1→6) linkages. All of these
enzymes function in glycogen metabolism in liver anding the first 24 hours was approximately 12 g, or 20%
of the absorbed dose. other tissues and can effectively metabolize icodextrin
to glucose. Since glycogen has a higher degree of-(1→6)Absorbed icodextrin is metabolized by plasma amy-
lase to smaller polymers including DP2, DP3 and DP4. branching than icodextrin, metabolism of icodextrin is
not constrained by the presence of -(1→6) branching.These small oligosaccharides are the principal metabolite
products of amylase hydrolysis of starch-derived poly- Kinetic parameters obtained from this study predict
steady-state levels of icodextrin and metabolites observedmers [19]. At the completion of the 12-hour dwell, plasma
concentrations of DP2 to DP4 accounted for 50% of during repeated (once daily) administration of icodex-
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trin. Steady-state plasma concentrations are estimated by higher blood levels), a greater degree of intraperitoneal
metabolism of icodextrin and a significant contributionthe formula C  K0/CL [where C  steady-state blood
to dialysate osmolality at the end of a four-hour dwellconcentration (g/L), K0  the zero-order absorption rate
(abstracts; Flessner et al, J Am Soc Nephrol 10:A1146,constant (g/h) and CL icodextrin clearance rate (L/h)].
2000; Garcia-Lopez et al, J Am Soc Nephrol 11:A1104,This predicted value of 5.26  0.46 g/L ( SE) is in
2000) [28]. Thus, in humans, the amount of intraperito-very close agreement with the steady-state plasma levels
neal metabolism of icodextrin is small and does not con-observed during long-term administration of icodextrin
tribute significantly to the rise in dialysate osmolality(4 to 6 g/L) [5, 8, 11]. The ability to accurately predict
during the dwell.steady-state levels from the single dose data lends addi-
Although a significant portion of absorbed icodextrintional credence to the first-order kinetic model, and indi-
is metabolized to glucose, icodextrin does not result incates that rates of elimination and metabolism of icodex-
hyperglycemia or hyperinsulinemia. This is in contrasttrin are not altered upon repeated administration. The
to concentrated dextrose-based solutions, which lead tolarge contribution of maltose and maltotriose to steady-
hyperglycemia and hyperinsulinemia as a result of thestate plasma icodextrin concentrations [3] also indicates
absorbed glucose load [29]. The absence of hyperglyce-continued metabolism by plasma amylase, in spite of the
mia and hyperinsulinemia in response to icodextrin may
inability to measure plasma amylase activity during ico- be related to its slower rate of absorption and the fact
dextrin administration due to assay interference (ab- that the metabolism to glucose occurs intracellularly
stract; Schonicke et al, J Am Soc Nephrol 10:A1163, 1999). rather than in the systemic circulation. These attributes
Previous studies have demonstrated that steady-state of icodextrin may ameliorate the weight gain and dyslipi-
levels of icodextrin and metabolites are constant for at demia that are believed to be due to the excessive glucose
least two years of administration with no evidence for load in peritoneal dialysis [30, 31]. In support of this
long-term accumulation, and that, upon discontinuation, hypothesis, patients receiving icodextrin in a random-
blood icodextrin levels return to baseline values with a ized, controlled, prospective trial had no increase in
similar kinetic profile even after many months of admin- weight after 52 weeks, contrasted to a weight gain of
istration [3, 10]. In 12 PD patients treated with icodextrin almost 2 kg in the dextrose control group (P  0.05)
for two years, plasma levels of icodextrin and maltose [11]. Additional evidence suggests that icodextrin may
returned to baseline within about seven days upon cessa- improve the lipid profile by lowering total cholesterol,
tion of icodextrin administration [3], similar to the elimi- low density lipoprotein (LDL) cholesterol, triglycerides
nation profile observed in this study. Re-administration and free fatty acids when compared to treatment using
dextrose-based solution [32].of icodextrin 21 days after cessation resulted in a return
The decline in serum sodium and chloride during ico-to previous steady-state levels without any rebound or
dextrin administration is likely related to a dilutionalovershoot effect. Because there is no change in the elimi-
effect due to an osmotic gradient caused by blood levelsnation pattern after repeated administration, these find-
of icodextrin and metabolites [33]. This hypothesis isings indicate that there is no capacity-limited deep body
supported by the close temporal relationship betweencompartment for icodextrin storage.
the serum sodium decline and rise in icodextrin bloodThe current study indicates that a small amount of ico-
levels in the present study (Fig. 9). The decline in serumdextrin metabolism occurs intraperitoneally during the
sodium is unlikely to be pseudohyponatremia, since mea-dwell; nevertheless, dialysate levels of icodextrin metab-
surements were made using an ion-selective electrodeolites do not contribute significantly to the rise in dialy-
and further investigation has not revealed any artifactsate osmolality. Since dialysate concentrations of DP3
in the measurement techniques. This dilutional hypo-and DP4 exceed blood levels at all time points (Fig. 7),
natremia is similar to that observed in cases of hypergly-the increase in peritoneal levels of these metabolites
cemia and in a case of maltose-induced hyponatremia,during the dwell is most likely explained by intraperito-
which was reported following administration of an intra-
neal metabolism by amylase. Although amylase activity venous solution containing 10% maltose [34]. The de-
in peritoneal effluents from PD patients is reported as crease in serum sodium and chloride is small (typically
undetectable or very low [25, 26], sufficient amylase may in the range of 2 to 3 mEq/L) and is not known to be
diffuse from blood to the dialysate to produce this small associated with any clinically adverse effect of icodextrin.
degree of intraperitoneal metabolism. The contribution Icodextrin and metabolites also are reported to increase
of icodextrin metabolites to the rise in dialysate osmolar- serum osmolality [33], although the rise in osmolality is
ity in this study was negligible (Table 3), consistent with small and less than the amount predicted by osmolar
previous findings [26, 27]. The rise in dialysate osmolality contribution of the metabolites, as a consequence of the
can be attributed to the increase in dialysate concentra- osmolal gap created by the decline in serum sodium. The
tions of urea, sodium and other solutes. These results osmolar effect of icodextrin metabolites may, however,
are in sharp contrast to those obtained in rats, for which oppose peritoneal ultrafiltration as suggested by the
modeling studies of Rippe and Levin [7].there was significant peritoneal amylase activity (due to
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dextrin Study Group: Efficacy and long-term safety of icodextrinIn conclusion, icodextrin plasma kinetics conforms to
in peritoneal dialysis. (in press, Am J Kidney Dis)a simple, single compartment model approximated by 12. Burke RA, Hvizd MG, Shockley TR: Direct determination of
zero-order absorption and first-order elimination, consis- polyglucose metabolites in plasma using anion-exchange chroma-
tography with pulsed amperometric detection. J Chromatogr B 693:tent with convective uptake via peritoneal lymphatics and
353–357, 1997steady rates of elimination and metabolism. Absorbed 13. Gibaldi M, Perrier D: One-compartment model, in Drug and the
icodextrin is metabolized by amylase to small oligo- Pharmaceutical Sciences: Pharmacokinetics, edited by Swarbrick
J, New York, Marcel Dekker, Inc., 1975, pp 27–30saccharides (maltose, maltotriose and maltotetraose). A
14. Rowland M, Tozer T: Constant-rate regimens (chapt 6), in Clini-small amount of intraperitoneal metabolism of icodex-
cal Pharmacokinetics: Concepts and Applications (2nd ed). New
trin occurs but does not contribute significantly to the York, Lea & Febiger Publishers, 1989, pp 63–77
15. Heimbu¨rger O, Waniewski J, Werynski A, Lindholm B: A quanti-rise in dialysate osmolality. The metabolism of absorbed
tative description of solute and fluid transport during peritonealicodextrin and the resultant rise in plasma levels of small
dialysis. Kidney Int 41:1320–1332, 1992
glucose polymers do not contribute to hyperglycemia or 16. Mactier RA, Khanna R: Peritoneal lymphatics, in Textbook of
hyperinsulinemia, but may result in a small decrease in Peritoneal Dialysis (2nd ed), edited by Gokal R, Khanna R, Kre-
diet R, Nolph KD, New York, Kluwer Academic Publishers, 2000,serum sodium and chloride. These new data fill the gaps
pp 173–192in our understanding of the pharmacokinetics and clini- 17. Mactier RA, Khanna R, Twardowski Z, et al: Contribution of
cal pharmacology of icodextrin. lymphatic absorption to loss of ultrafiltration and solute clearances
in continuous ambulatory peritoneal dialysis. J Clin Invest 80:1311–
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